<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-59679</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">What is special about adalimumab?</dc:title>
<dc:description xml:lang="en">Adalimumab is the first fully human anti-tumor necrosis factor (TNF-&amp;#945;) monoclonal antibody and it binds to both soluble and cell-bound TNF-&amp;#945;, modulating biological responses linked to this cytokine. Different trials have probed the efficacy of adalimumab even after one week, and accumulated experience in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn´s disease shows adalimumab as a safe drug sharing a similar adverse effects profile with the other anti-TNF-&amp;#945; molecules. Specific features of adalimumab are revised (AU)</dc:description>
<dc:creator>Rodríguez-Blanco, I</dc:creator>
<dc:creator>Toribio, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Adalimumab es el primer anticuerpo monoclonal anti-factor de necrosis tumoral alfa (TNF-&amp;#945;) completamente humano que se une con una alta afinidad tanto a la forma soluble como a la forma unida a células del TNF-&amp;#945;, modulando su actividad biológica. Varios ensayos clínicos han demostrado la eficacia y rapidez de acción de adalimumab en pacientes con psoriasis, y la experiencia de uso en enfermedades como la artritis reumatoide, artritis psoriásica, espondilitis anquilosante y enfermedad de Crohn lo posicionan como un fármaco seguro, con un perfil de efectos secundarios similar a otros fármacos anti-TNF-&amp;#945;. Las peculiaridades específicas de esta molécula son revisadas en este artículo (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.3): 28-32, feb. 2008. tab</dc:source>
<dc:identifier>ibc-59679</dc:identifier>
<dc:title xml:lang="es">¿Qué tiene de singular adalimumab?</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1716^s22074</dc:subject>
<dc:subject>^d29646</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d23973^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d1716^s22066</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d1716^s22045</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d27231^s22011</dc:subject>
<dc:subject>^d29591^s22073</dc:subject>
<dc:subject>^d31092^s22021</dc:subject>
<dc:subject>^d27231^s22078</dc:subject>
<dc:subject>^d920^s22021</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d29591^s22078</dc:subject>
<dc:subject>^d29591^s22079</dc:subject>
<dc:subject>^d13552^s22057</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d24527^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200802</dc:date>
</metadata>
</record>
</ibecs-document>
